Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Forman

Showing results (891-900 of 1,052) with videos related to

Pageof 106
Sort By:
American Journal of Hematology|December 30, 2014
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasmPamela S Becker, Bruno C Medeiros, Anthony S Stein, et al.
Haematologica|July 20, 2023
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphomaJames Godfrey, Matthew Mei, Lu Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 1, 1996
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host diseaseN J Chao, P M Parker, J C Niland, et al.
Blood Advances|June 22, 2021
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplantMonzr M Al Malki, Ni-Chun Tsai, Joycelynne Palmer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2020
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaAmandeep Salhotra, Dongyun Yang, Sally Mokhtari, et al.
American Journal of Hematology|July 7, 2020
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemiaIbrahim Aldoss, Jianying Zhang, Matthew Mei, et al.
The Lancet. Haematology|February 9, 2016
Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialRyotaro Nakamura, Corinna La Rosa, Jeffrey Longmate, et al.
Leukemia|January 18, 2022
CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemiaXiuli Wang, Zhenyuan Dong, Dennis Awuah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2015
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent GlioblastomaChristine E Brown, Behnam Badie, Michael E Barish, et al.
JAMA Oncology|January 19, 2023
Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow TransplantAndrew McDonald, Chen Dai, Qingrui Meng, et al.
Pageof 106

Showing results (891-900 of 1,052) with videos related to

Sort By:
Pageof 106
American Journal of Hematology|December 30, 2014
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasmPamela S Becker, Bruno C Medeiros, Anthony S Stein, et al.
Haematologica|July 20, 2023
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphomaJames Godfrey, Matthew Mei, Lu Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 1, 1996
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host diseaseN J Chao, P M Parker, J C Niland, et al.
Blood Advances|June 22, 2021
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplantMonzr M Al Malki, Ni-Chun Tsai, Joycelynne Palmer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2020
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaAmandeep Salhotra, Dongyun Yang, Sally Mokhtari, et al.
American Journal of Hematology|July 7, 2020
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemiaIbrahim Aldoss, Jianying Zhang, Matthew Mei, et al.
The Lancet. Haematology|February 9, 2016
Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialRyotaro Nakamura, Corinna La Rosa, Jeffrey Longmate, et al.
Leukemia|January 18, 2022
CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemiaXiuli Wang, Zhenyuan Dong, Dennis Awuah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2015
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent GlioblastomaChristine E Brown, Behnam Badie, Michael E Barish, et al.
JAMA Oncology|January 19, 2023
Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow TransplantAndrew McDonald, Chen Dai, Qingrui Meng, et al.
Pageof 106